NASDAQ:AARD - Nasdaq - US0029421007 - Common Stock - Currency: USD
NASDAQ:AARD (5/30/2025, 1:13:28 PM)
10.52
+0.22 (+2.14%)
The current stock price of AARD is 10.52 USD. In the past month the price decreased by -7.29%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 53.46 | 697.14B | ||
JNJ | JOHNSON & JOHNSON | 15.39 | 372.10B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 19.89 | 314.59B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.83 | 226.99B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.51 | 225.27B | ||
MRK | MERCK & CO. INC. | 9.91 | 193.85B | ||
PFE | PFIZER INC | 7.32 | 133.52B | ||
SNY | SANOFI-ADR | 11.2 | 119.92B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.55 | 97.87B | ||
GSK | GSK PLC-SPON ADR | 9.25 | 83.15B | ||
ZTS | ZOETIS INC | 28.12 | 75.36B | ||
HLN | HALEON PLC-ADR | 23.12 | 51.02B |
Aardvark Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in San Diego, California and currently employs 22 full-time employees. The company went IPO on 2025-02-13. The firm targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. The company is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
AARDVARK THERAPEUTICS INC
4370 La Jolla Village Drive, Suite 1050
San Diego CALIFORNIA US
Employees: 22
Phone: 18582257696
The current stock price of AARD is 10.52 USD. The price increased by 2.14% in the last trading session.
The exchange symbol of AARDVARK THERAPEUTICS INC is AARD and it is listed on the Nasdaq exchange.
AARD stock is listed on the Nasdaq exchange.
10 analysts have analysed AARD and the average price target is 32.13 USD. This implies a price increase of 205.42% is expected in the next year compared to the current price of 10.52. Check the AARDVARK THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AARDVARK THERAPEUTICS INC (AARD) has a market capitalization of 228.28M USD. This makes AARD a Micro Cap stock.
AARDVARK THERAPEUTICS INC (AARD) currently has 22 employees.
AARDVARK THERAPEUTICS INC (AARD) has a support level at 9.88 and a resistance level at 10.45. Check the full technical report for a detailed analysis of AARD support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AARD does not pay a dividend.
AARDVARK THERAPEUTICS INC (AARD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.96).
The outstanding short interest for AARDVARK THERAPEUTICS INC (AARD) is 1.87% of its float. Check the ownership tab for more information on the AARD short interest.
ChartMill assigns a technical rating of 4 / 10 to AARD.
ChartMill assigns a fundamental rating of 3 / 10 to AARD. While AARD has a great health rating, there are worries on its profitability.
Over the last trailing twelve months AARD reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS decreased by -185.61% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -24.59% | ||
ROE | -25.55% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to AARD. The Buy consensus is the average rating of analysts ratings from 10 analysts.